Hanmi, Lundbeck Korea to reinforce local co-marketing of Ebixa for treatment of moderate to severe A

Hanmi Pharm said on November 27 that it has signed an agreement with Lundbeck Korea with an aim to co-promote Ebixa (memantine 10mg), anti-dementia agent, in Korea for the next five years.

A November 26 signing ceremony were attended by Hanmi’s president Chang An-soo; his Lundbeck counterpart LØkke Pedersen; Morten Bryde Hansen, vice president.

Ebixa is an uncompetitive, moderate affinity...